Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

umeclidinium

umeclidinium
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Incruse Ellipta AEROSOL POWDER, INHALATION 62.5 mcg/inh    
Comments:

Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

umeclidinium (Incruse Ellipta)

  • 62.5 mcg one inhalation daily

ipratropium nebulization

  • 0.5 mg neb every 6 hours

Reviewed: 27 January 2017 (Incruse Ellipta)

Last updated: Mar. 3, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved